Five notes:
1. BCBSMA reported an after-tax third quarter net income of $29.2 million on revenue of $2.4 billion (1.21% net margin).
2. Year-to-date, BCBSMA reported an after-tax net income of $27.1 million on revenue of $7.2 billion (0.38% net margin).
3. The company’s operating loss in the third quarter was $19.8 million. Compared to a year ago, Q3 operating income is down $145 million and net income is down $135.1 million.
4. 2,000 members are starting GLP-1 medications every month, and spending on GLP-1s has risen by 250% since last year, putting the company on track to spend nearly $200 million on the medications in 2024.
5. “We continue to see a significant escalation in spending on medical and pharmacy services; in fact, the growth in spending is the highest in at least a decade,” CFO Ruby Kam said. “While the increase in spending is across almost all categories of services, the growth in spending on new and popular GLP-1 weight loss medications is worth noting.”
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.